Sarcopenia is a progressive and generalised skeletal muscle disorder. It is characterised by the loss of muscle mass and strength. Sarcopenia treatment products such vitamin D and protein supplements are used for treating sarcopenia. Such supplements help in increasing muscle mass and strength. With the growing geriatric population globally, the prevalence of sarcopenia is also increasing rapidly. As per the analysis, geriatric population aged 65 years and above is the most vulnerable to sarcopenia.

The global Sarcopenia Treatment Market is estimated to be valued at US$ 3.01 Bn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

The increasing geriatric population is one of the major factors propelling the growth of the sarcopenia treatment market. As per the United Nations reports, in 2050, one in six people in the world will be over age 65 (16%), up from one in 11 in 2019 (9%). By 2050, one in four persons living in Europe and North America could be aged 65 or over. The number of older persons globally is projected to grow dramatically from 703 million in 2019 to 1.5 billion in 2050. This burgeoning geriatric population is making them highly prone to sarcopenia. As per estimates, over 50% of people over 80 years experience sarcopenia. Hence, rising aging population globally is expected to drive considerable demand for sarcopenia treatment products during the forecast period.

SWOT Analysis

Strength: Sarcopenia treatment options available address the root causes of muscle loss and focus on improving muscle quality and physical performance. Newer treatment options like testosterone replacement therapies and other anabolic drugs are effective in gaining muscle mass.
Weakness: High costs associated with treatment and supportive care. Lack of standardized definition and diagnostic guidelines for sarcopenia make it difficult to estimate disease prevalence and burden.
Opportunity: Increasing elderly population worldwide prone to sarcopenia raises the potential patient pool. Growing public health awareness regarding exercise and diet modification for sarcopenia prevention presents an opportunity.
Threats: Low treatment adherence and lack of physical activity even after treatment. Alternative therapies like herbal medicines pose competition.

Key Takeaways

The global Sarcopenia Treatment Market Share is expected to witness high growth.

Regional analysis related content comprises the North American region currently dominates the sarcopenia treatment market and is expected to continue its dominance over the forecast period. Growth in elderly population, rising awareness about sarcopenia treatment, and adoption of innovative treatment options drive the regional market growth.

Key players related content comprises Key players operating in the sarcopenia treatment market are Abbott Laboratories, Novartis AG, Eli Lilly and Company, Merck & Co., Inc., GlaxoSmithKline plc. Major players focus on new drug approvals and launches, collaborations, acquisitions, and geographic expansion to consolidate their market shares in various regions.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it